Lazuline Biotech to develop new drug for prevention and treatment of Cancer
and Alzheimer's disease with National Cheng Kung University in Taiwan
Lazuline has added another meaningful collaboration to its existing research and development efforts to positively impact the healthcare industry. The agreement with NCKU based in Taiwan is to advance the drug and vaccine development for Alzheimer's Disease and cancer. This marks a significant milestone in international collaborations.
This association is in light of the discovery of a small drug peptide named "Zfra" or "Zffi" by distinguished
professor Nan-Shan Chang at the Institute of Molecular Medicine of NCKU. The research teams from both NCKU and
LBPL will work together on Zffi to develop drug and vaccine and are expecting the clinical trials to be initiated
in India between 2022 and 2023 considering the completion of significant R&D work.
Alzheimer's disease (AD) is an abnormal aging process of the brain that effects the normal way of our thinking,
memory, social behavior and communication skills. This is also considered as the most common type of dementia among the elderly.
Mr. Chang quoted that "Currently there are no effective drugs in treating and preventing AD on the market. If Zffi works properly,
it is expected to mitigate AD progression with age". As a technical innovation, Chang group has developed a single immunization shot of Zffi in individuals at childhood and middle ages.
The treatment can activate a novel link in the immune system to fend off cancer and retard neurodegeneration as one grows older.
According to Chang, the underlying mechanism for Zffi action is mainly due to Zffi activation of the body's
immune system. Aside from the widely known T and B cells, he discovered a novel lineage of immune cells in
the spleen called "Z cell". Zffi activates the spleen Z cells in the body to fight against the progression of cancer and AD.
Accordingly, Zffi is now being developed as a vaccine for Z cell activation. Activated Z cells can recognize the presence
of cancer cells in the body and sense the progression of neurodegeneration in the brain. Z cells manage to block and prevent
the disease progression.
For the development of a new drug, the effort from bench work to clinical trials is enormous and is likely to take a considerable
amount of time stretching into years. In most cases, the likelihood of failure is very high. The joined effort between LBPL
and NCKU can accelerate and streamline the drug development process. Experts from both the teams are confident in paving
the way toward success and its benefit to the mankind.
Dr Giri, General Manager R&D at LBPL, an alumnus of the microbiology and Immunology Institute at NCKU, is aware of the international
influence that medical research at NCKU has. After he returned to India, he kept seeking opportunities for transnational
collaborations with advanced pharmaceutical companies, and he became the main contributor behind this transnational
collaboration between NCKU and Lazuline Biotech. The pioneering academic achievements and new drug manufacturing processes of
research teams at NCKU have a promising future.
The exchanges in ideas, differences and common interests between Lazuline and NCKU had lasted more than a year, and each decision
was made after careful deliberation. With this collaboration LBPL hopes to be a major contributor to the advancement of
the Alzheimer's cure.